Oxycodone/naltrexone - Elite Pharmaceuticals

Drug Profile

Oxycodone/naltrexone - Elite Pharmaceuticals

Alternative Names: Abuse resistant oxycodone; ELI-200; ELI-201; ELI-216; Naltrexone/oxycodone - Elite Pharmaceuticals; Oxy-Nal; Oxycodone hydrochloride/Naltrexone - Elite Pharmaceuticals; OxyNal™; SequestOx

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elite Pharmaceuticals
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Preregistration Pain
  • Phase III Postoperative pain

Most Recent Events

  • 12 Sep 2018 Chemical structure information added
  • 05 Feb 2018 Elite Pharmaceuticals initiates enrolment in a phase I trial for Pain (In volunteers) (Before January 2018)
  • 30 Jan 2018 Preregistration for Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top